Overview of Urografin 76%

Quick Facts

Property	Description
Active ingredient	Meglumine Amidotrizoate, Sodium Amidotrizoate
Form	Solution for Injection (76% concentration)
Pharmacological class	X-ray Contrast Media (Diagnostic Agent)
Common use	Enhanced visualization for diagnostic imaging
Origin	Synthetic (Triiodinated benzoic acid derivative)

What is Urografin 76% and What is its Classification?

Urografin 76% is a specialized diagnostic agent that belongs to the pharmacological class of X-ray Contrast Media, used solely to enhance the clarity of internal body structures during medical imaging procedures. This preparation is chemically known as an ionic, water-soluble contrast medium and possesses no therapeutic function to treat or cure diseases. It provides enhanced visualization, enabling healthcare professionals to accurately assess the structural integrity of internal organs and blood vessels that are otherwise indiscernible on standard X-ray images. This specific formulation is an established iodine-containing contrast agent, clinically recognized for its reliable performance in contrast-enhanced radiography procedures.

Composition and Physical Form of Urografin 76%

The core of Urografin 76% is its active formulation, which consists of a precisely balanced mixture of two Diatrizoate Salts, specifically Meglumine Amidotrizoate and Sodium Amidotrizoate. These active ingredients are synthetic compounds derived from triiodinated benzoic acid. A distinctive feature of Urografin 76% is its high-concentration (76%) aqueous Solution for Injection, designed for parenteral administration. This high-concentration, two-salt combination is a specific formulation feature that ensures the product is highly soluble and stable for rapid systemic distribution following administration.

The Mechanism of Contrast: Why the Iodine Matters

The diagnostic utility of Urografin 76% is due to its substantial iodine content, which facilitates a physical mechanism known as X-ray attenuation. When the solution flows through a body structure, this dense iodine efficiently absorbs X-rays, causing the structure to appear highly opaque—a process referred to as opacification. This principle allows for the clear differentiation of structures, fulfilling the drug's essential diagnostic purpose by creating the necessary sharpened contrast for assessing anatomy within the body. This compound is rapidly excreted, primarily via the kidneys, a predictable characteristic that aids in post-procedure clearance.

What side effects are possible with Urografin 76%?

Possible Side Effects and Safety Information

The safety profile for Urografin 76% (Diatrizoate salts) is formally documented in regulatory sources by classifying adverse reactions based on frequency and the physiological systems affected. These official classifications range from common, anticipated effects to rare, serious systemic events.

Official Adverse Reaction Categories

Adverse effects are categorized by frequency, which includes reactions classified as Common (occurring in ge 1/100 patients, such as nausea, vomiting, or a sensation of general warmth/flushing), Uncommon (e.g., thrombophlebitis, vasovagal reactions), and Rare (e.g., thromboembolic events or convulsions). These effects are documented across multiple System-Organ Classes, including Cardiovascular Disorders, Nervous System Disorders, and Gastrointestinal Disorders.

Serious Adverse Reactions

The product label explicitly lists serious, although rare, adverse reactions. These include severe Anaphylactoid/Hypersensitivity Reactions (such as shock or severe hypotension), Cardiac Disorders (including cardiac arrest and ventricular fibrillation), and Severe Cutaneous Adverse Reactions (SCARs) like Stevens-Johnson Syndrome (SJS).

Population-Specific and Time-Related Safety Notes

Regulatory documents highlight increased safety consideration for specific populations. For instance, newborns and preterm infants require monitoring due to the potential for transient hypothyroidism. Patients with severe cardiac disease also have an officially noted increased risk of severe reactions. Most documented adverse reactions typically occur within one hour of administration, though delayed reactions are possible. High-level safety constraints include the contraindication for inadvertent intrathecal use and specific warnings regarding intravascular use in patients being treated with Metformin, which may lead to lactic acidosis.

Overdose and Emergency Response

Urografin 76% overdose is officially documented to present with severe systemic effects due to its high concentration. Manifestations may include hypotension and hypovolemia, resulting from fluid shifts caused by the hyperosmolar solution. Severe changes in serum osmolarity and electrolyte concentrations are documented and may lead to shock-like states. Overexposure or severe adverse reactions can escalate to life-threatening outcomes, including circulatory failure, ventricular fibrillation, and cardiac arrest. Acute complications also include the risk of acute renal failure, particularly in patients with pre-existing conditions like multiple myeloma.

In the event of a suspected overdose or a severe reaction, the administration must be discontinued immediately, and immediate medical attention must be sought. Official regulatory guidance mandates the prompt institution of symptomatic therapy directed toward the support of all vital functions. No specific antidote is known for this contrast agent; management focuses on supportive measures, including correcting fluid balance, and may involve dialysis in cases of severe overdose or greatly impaired kidney function. Patients must be kept under close observation for at least 30 minutes after administration, with immediate countermeasures made available. Specific patient groups, such as older individuals with cardiac disease and neonates, have documented population-specific considerations regarding risk and monitoring.

Therapeutic Uses of Urografin 76%

What Urografin 76% Treats: Main Uses and Benefits

Urografin 76% is primarily applied across domains where additional symptomatic support is needed due to underlying structural uncertainty, particularly when symptoms relate to physical discomfort or noticeable physiological strain. Its main role may assist in providing informational clarity in diagnostic procedures, including urography for kidney and bladder assessment, angiography for vascular studies, CT enhancement for soft tissue differentiation, and specialized cavity and GI studies.

This capability supports symptom management by assisting in the diagnostic process. Its primary benefit generally involves providing visualization that may assist in determining the structural cause of the patient’s discomfort. In these contexts, its use is relevant when supportive symptom management is appropriate, as it advances the diagnostic plan. This approach is also relevant when symptoms become temporarily overwhelming, where supportive symptomatic assistance may be needed.

Property	Description
Quick Fact: Support for Diagnosis	The core benefit is informational support, which contributes to managing symptoms by assisting in the resolution of structural uncertainty.

Eligibility and Restrictions for Use

Who can and cannot use Urografin 76%?

The eligibility for Urografin 76% (Diatrizoate Meglumine and Diatrizoate Sodium Injection) is strictly governed by regulatory documentation, establishing both absolute prohibitions and required use restrictions.

Populations with Absolute Contraindications

Use is contraindicated for patients with:

Known hypersensitivity to diatrizoic acid salts or iodinated contrast media.
Uncontrolled thyrotoxicosis (manifest hyperthyroidism) or decompensated cardiac insufficiency.
Procedures involving intrathecal administration (e.g., myelography), which is prohibited.
Anuria or dehydrated azotemic patients (for urography procedures).

Eligibility Restrictions and Special Populations

Organ and Comorbidity Restrictions: Use in severe renal failure, Multiple Myeloma, and concomitant hepatorenal disease requires caution. Preparatory dehydration is officially omitted for these groups, and adequate hydration is mandatory.
Age Groups: Preparatory dehydration is labeled as dangerous and must be strictly avoided in infants, young children, and the elderly.
Reproductive Status: The procedure of Hysterosalpingography is contraindicated in pregnancy. General use during lactation is not recommended due to the passage of the agent into human milk.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Urografin 76%

Interaction Scope

Property	Documentation (Strictly Regulatory)
Medicinal product categories with documented interactions	Biguanides (Metformin), Nephrotoxic Drugs, Iodinated Radiopharmaceuticals (I-123, I-131 agents), Vasopressors.
Specific interacting medicines (if explicitly listed)	Metformin, Iobenguane I-123, Sodium Iodide I-131.
Mechanistic basis of interactions (only if stated in label)	Decreased renal clearance of co-administered drugs; Interference with diagnostic tests (radioactive iodine uptake, PBI); Additive risk of organ toxicity (nephrotoxicity); Potentiation of neurologic effects (with vasopressors).
Timing-based interaction rules (if applicable)	Mandatory temporary discontinuation of Metformin (e.g., 48 hours before and after procedure) in defined patient groups; Delay of Protein-Bound Iodine (PBI) testing for at least 16 days post-administration due to interference.
Population-specific interaction notes (if applicable)	Metformin discontinuation is specifically required for patients with eGFR < 30 mL/min/1.73 m² or eGFR 30-60 mL/min/1.73 m² with co-morbid risk factors such as hepatic impairment or heart failure.
Interaction-related restrictions	Do not administer following the injection of vasopressors; Avoid co-administration with other nephrotoxic agents.

Interaction Classifications (High-Level)

Property	Documentation (Strictly Regulatory)
Interaction severity classification (as defined in official documents)	Contraindicated Combination (with Metformin in specific patient populations); Clinically Significant Interaction.
Regulatory basis (EMA / FDA / etc.)	Formal regulatory constraints established by FDA (Prescribing Information / DailyMed) and EMA (SmPC).
Interaction-context constraints (as defined in official documents)	Constraints tied to the risk of lactic acidosis (Metformin), acute renal injury (nephrotoxic agents), and diagnostic test interference (radioactive iodine/PBI testing).

Resulting Interaction Structure

Official interaction statements:

The co-administration of iodinated contrast media with Metformin is formally designated as a contraindicated combination in patients with renal impairment or other conditions that increase the risk of lactic acidosis.
Urografin 76% is documented to decrease the renal clearance of certain co-administered drugs, including Metformin and specific iodinated radiopharmaceuticals (e.g., Iobenguane I-123), leading to increased plasma exposure.
Regulatory documents establish mandatory timing separation rules for Metformin and Protein-Bound Iodine (PBI) testing following the administration of the contrast agent.
The profile notes a pharmacodynamic interaction involving the interference with the thyroid gland's uptake of radioactive iodine (I-131 or I-123 diagnostic agents).

Connection to the overall interaction profile:

The regulatory documents define the product’s interaction structure primarily through two domains: pharmacokinetic modification involving decreased renal clearance of co-administered agents like Metformin, and pharmacodynamic interference related to the iodine content affecting thyroid diagnostic procedures. These documented interactions establish mandatory restrictions, including a formal classification of the Metformin combination as contraindicated in specific patient groups, and enforce timing rules for subsequent diagnostic tests.

Mechanism of Action

Physical Basis: X-ray Photon Attenuation

The primary mechanism is physical, not biochemical. It acts on the X-ray electromagnetic spectrum, utilizing the high atomic number of its iodine atoms to efficiently absorb and scatter incident X-ray photons (attenuation). This core mechanism temporarily transforms the fluid in blood vessels and excretory organs into a dense, radiopaque medium. This leads to the demarcation of the structures by radiodensity.

Systemic Action: Passive Distribution and Renal Clearance

The drug functions as a simple, non-metabolized extracellular fluid tracer. Following rapid intravenous injection, it passively distributes into the vascular and interstitial spaces. Its main systemic pathway involves rapid and near-total filtration at the renal glomerulus with minimal reabsorption. This mechanism leads to the high concentration of the contrast agent within the urinary collecting system, contributing to the concentration of the contrast agent within the structures of the renal excretory system. The effect is transient due to its rapid and efficient excretion by the renal pathway.

Secondary Effect: Transient Osmotic Modulation

The high concentration of the active salts in Urografin imparts high osmolality to the solution. This property initiates a transient osmotic effect where water is drawn into the vascular space upon injection, or into the gastrointestinal lumen if administered orally. This process temporarily modulates local fluid dynamics within the body compartments it occupies.

Dosage and Administration Information

Urografin 76% is utilized solely as a specialized diagnostic agent and is administered under a strictly defined protocol in a controlled clinical environment. Its use is standardized based on the type of imaging study being performed.

Administration Routes and Dosing Patterns

The contrast medium is administered primarily by the intravascular route, specifically as an intravenous (IV) or intra-arterial injection, or via local injection into body cavities for specific radiological procedures. The official formulation is a 76% Solution for Injection, corresponding to 370 mg of iodine per mL.

Procedure Context	Standard Dose	Administration Condition
IV Urography (Adult)	20 mL (up to 50 mL)	Injection rate generally 20 mL/minute
IV Urography (Pediatric)	Age-dependent volumes (e.g., 7 to 10 mL for le 1 year)	Requires careful dosage assessment

Procedural Requirements

Administration requires specific pre-procedure preparations. Patients must ensure adequate hydration before and after the procedure. The solution should be warmed to body temperature (37 C) prior to use to optimize flow and must be drawn into the syringe immediately before injection. For abdominal examinations, temporary pre-procedure dietary modifications, such as avoiding flatulent foods, are specified. Following the single administration, patients are kept under observation for a minimum of 30 minutes. The dose is kept as low as possible when administering to patients with renal or cardiovascular impairment. The product is intended for single-use only, and any unused portion must be discarded after the procedure.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Urografin 76%

Evidence for Visualization in Urography

Urografin 76% was studied for its use in urography, a type of diagnostic imaging that focuses on the kidneys, ureters, and bladder. The research base includes controlled clinical trials and physiological assessments, which research examined how the agent provides visual contrast within the renal system. Studies monitored outcomes related to the agent's ability to outline anatomical structures. The research for this indication often focused on general adult patient cohorts.

Studies reported measurements of image quality observed in the evaluated cases. Physiological assessments studies explored the concentration of the contrast medium that appeared in the urine, which provides insight into the predictable process of renal excretion. Historical documentation describes the agent's role in supporting opacification for diagnostic purposes in clinical settings. Evidence is limited regarding long-term outcomes following the use of this agent, as most research focused strictly on the immediate diagnostic timeframe.

Evidence for Visualization in Angiography

The agent was evaluated in research exploring angiography, a procedure involving the visualization of blood vessels. These studies primarily involved physiological assessments and controlled trials, which research examined both the clarity of vascular delineation and the acute effects of the injection on the patient's system. Study populations included adult patients undergoing various forms of vascular assessment.

Research data show patterns related to measurements of vascular delineation. Physiological assessments studies monitored transient changes in immediate systemic parameters, such as the temporary alteration in circulating blood volume that was associated with the rapid injection of the contrast medium. Long-term effects are not fully established, and follow-up durations were limited in many of the core studies. Comparative evidence is lacking for a direct assessment of this high-osmolality, ionic agent against lower-osmolality non-ionic agents in modern randomized trials regarding diagnostic yield.

Research Gaps and Uncertainties

The research base demonstrates that evidence quality varies across studies, with many core reports relying on older designs, including smaller physiological or observational studies. There is a general lack of modern, large-scale, controlled trials comparing Urografin 76% directly against the newer non-ionic contrast agents. These limitations mean that while the agent's core function is historically established, data are still emerging for comparative diagnostic yield and long-term consequences, particularly for specific patient subgroups.

Frequently Asked Questions (FAQ)

Common questions about Urografin 76% (FAQ)

Q: What kind of medical scans is Urografin 76% typically used for?

Urografin 76% is a specialized diagnostic agent used to enhance visualization during various medical imaging procedures. Official product information indicates its use in X-ray imaging, CT scans, angiography (blood vessel imaging), urography (urinary system imaging), and studies of the gastrointestinal tract and joints. The purpose is to temporarily improve the contrast of internal body structures.

Q: Is Urografin 76% the same as the "dye" used for CT scans?

Yes, Urografin 76% is a type of iodine-containing contrast agent used during CT scan examinations. The iodine content temporarily enhances the contrast of internal structures, allowing for clearer diagnostic images. This effect is transient and relates only to the imaging process.

Q: Can Urografin 76% be used as an alternative to barium for GI studies?

According to official product descriptions, this agent may be used to image the gastrointestinal tract. It is specified as a potential alternative to the use of barium sulfate in certain circumstances, such as when a bowel perforation is suspected or when a patient has a known barium allergy.

Q: How quickly does Urografin 76% start working after injection?

Following intravenous injection, the agent distributes rapidly into the vascular and interstitial spaces. Official pharmacological studies indicate the agent begins to be cleared by the kidneys almost immediately after administration. This rapid action results in a quick but temporary opacification effect.

Q: Can Urografin 76% cause nausea or a metallic taste in the mouth?

Yes, regulatory documents note that it is common for patients to notice a temporary metallic taste in the mouth shortly after administration. Patients may also experience nausea. These effects are typically mild and are generally expected to subside shortly after the procedure is complete.

Q: Is there a risk of delayed reactions after leaving the clinic?

Most documented adverse reactions occur within the first hour of administration while the patient is under observation. However, official information notes that delayed reactions are possible in rare cases. These rare delayed reactions may occur hours or even days after the procedure is complete.

Q: How long after the scan should I monitor for signs of a reaction?

While patients are typically monitored by staff for at least 30 minutes following the procedure, rare delayed reactions can still occur. For this reason, official safety information suggests patients monitor themselves for any unexpected symptoms for up to several days. If symptoms of concern occur after leaving the clinic, contact should be made with a healthcare professional.

Q: Can a patient with asthma still receive Urografin 76%?

Official product information notes that the risk of experiencing an adverse reaction to contrast media may be higher for patients with a history of bronchial asthma. This condition requires a particularly careful risk-benefit assessment before the agent is administered.

Q: Is Urografin 76% used during pregnancy?

There is limited data available in regulatory documents regarding the general safety of Urografin 76% during pregnancy. If the agent is used during pregnancy, official recommendations state that thyroid function monitoring may be needed for newborns who were exposed to the iodine content while in utero.

Q: Are there any blood pressure medicines that might interact with Urografin 76%?

Official interaction statements list specific medicinal categories that may interact with Urografin 76%. Documented interactions include medicines that act as vasopressors and may involve other classes of drugs used for heart or blood pressure conditions, such as beta-blockers.

Q: Is there a known interaction between Urografin 76% and alcohol?

Official patient safety information notes that the consumption of alcohol is not recommended in connection with the use of this medicine. This restriction is advised because alcohol may increase the chances of experiencing adverse medicinal interactions.

Q: What makes Urografin 76% different from other common contrast agents?

Urografin 76% is chemically classified as an ionic, high-osmolality contrast agent containing Diatrizoate salts. This chemical classification forms the basis of its difference from newer contrast media, which are typically defined as non-ionic.

Q: Is Urografin 76% an "older" type of contrast dye?

The classification of Urografin 76% as an ionic contrast medium is a historical classification. This compound class was developed and utilized prior to the widespread introduction of newer, non-ionic contrast agents.

Q: Is the iodine concentration of Urografin 76% considered high compared to other contrast media?

Yes, the agent is officially identified as a high-concentration solution in its product description. This specific formulation contains 370 mg of iodine per mL of solution.

Q: Does the way the contrast is administered (IV, by mouth, etc.) change the risk level?

The risk profile for the agent is dependent on the route through which it is administered. Regulatory warnings specify that intrathecal administration (injection into the spinal fluid) is prohibited due to the risk of neurotoxic symptoms.

Q: Why is it important to fast before a procedure using Urografin 76%?

For some procedures, especially those involving X-rays of the abdomen or kidneys, regulatory procedural requirements indicate that patients may be asked to fast from the evening before. This pre-procedure preparation, which may also include dietary changes, helps to ensure the imaging area is clear for optimal visualization.

Q: Who is qualified to administer Urografin 76%?

Official documentation states that the administration of this agent is restricted to an experienced clinician, trained individual, or qualified medical staff (such as a doctor or radiographer). The product label specifies that the agent is not intended for self-administration.

Q: Does Urografin 76% affect a patient's ability to drive after the procedure?

Official patient information includes a warning that caution is necessary regarding driving or using machines after the procedure. This warning is based on the possibility of delayed reactions occurring, which could potentially impair a patient's physical abilities.

How should Urografin 76% be stored and disposed of?

Storage and Disposal of Urografin 76%

Urografin 76% requires specific handling to maintain its stability as an X-ray contrast medium. The product must be stored below 30°C (86°F) and protected from both light and secondary X-rays. Exposure to cold temperatures may cause crystallization, necessitating warming the solution to ensure complete dissolution prior to use.

Handling and Safety

To maintain sterility, the vial stopper should never be pierced more than once. The solution should be drawn into the syringe immediately before administration. Any warming of the solution for viscosity reduction should not exceed three months in total. As with all medicines, Urografin 76% must be kept out of the sight and reach of children.

Disposal

Unused or expired product must not be discarded with household trash or poured into wastewater. Disposal must be performed in accordance with local regulations and protocols for pharmaceutical waste.

Urografin 76%